Plain-English translation of NCT07095452 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new investigational medication called , given intravenously (through an IV), combined with another drug called for people with newly diagnosed multiple myeloma who are not candidates for stem cell transplant. The study will compare this new treatment combination to the current standard treatment to see if it works better and causes fewer side effects. About 660 patients will participate across roughly 155 hospitals and clinics worldwide.
Multiple myeloma is a serious blood cancer that can cause bone pain, fractures, infections, and kidney problems. While stem cell transplant works well for some patients, many older or frailer patients cannot tolerate this intensive procedure. This trial is exploring whether this new medication could offer a better option for these patients who need effective treatment but cannot have a transplant.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive either the new medication combination ( plus ) or the current standard treatment (, , and ) given by IV infusions or injections at regular clinic visits. You will have frequent hospital or clinic appointments over approximately 16 years for blood tests, physical exams, side effect monitoring, and questionnaires to track how the treatment is working. The study involves more frequent visits than your usual care, and your doctor will carefully monitor your response to treatment and any side effects throughout your participation.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States